Literature DB >> 26224305

Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis.

Kathleen Morrisroe1, Melinda Wong2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26224305     DOI： 10.1093/rheumatology/kev275

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  6 in total

1.  Persistent eosinophilia in rheumatoid arthritis: a prospective observational study.

Authors:  Dantis Emmanuel; Subhash Chandra Parija; Ankit Jain; Durga Prasanna Misra; Rakhee Kar; Vir Singh Negi
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

Review 2.  Hematologic side effects of biologics and kinase inhibitors used in rheumatologic diseases: a review of the current evidence.

Authors:  Sambhawana Bhandari; Maun Ranjan Baral; Matthew Barbery; Alla Rudinskaya; Oleg Sostin
Journal:  Ann Hematol       Date:  2022-06-27       Impact factor: 4.030

3.  Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis.

Authors:  Naoto Azuma; Kiyoshi Matsui; Naoaki Hashimoto; Takahiro Yoshikawa; Hajime Sano
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

4.  Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis.

Authors:  Rose I Massolino; Pravin Hissaria; Anita Lee; Susanna M Proudman
Journal:  Rheumatol Adv Pract       Date:  2018-09-17

5.  When Autoimmunity 'DRESSes up': A Case after Certolizumab Therapy.

Authors:  Benedetta Marigliano; Federico Rosa; Mattia Internullo; Luigi Scuro; Andrea Tavanti; Lucia Rita Del Vecchio; Francesco Paolo Romagno; Maria Barbara Schito; Federica Pace; Giovanni Maria Colombo; Emanuele Guglielmelli
Journal:  Eur J Case Rep Intern Med       Date:  2022-07-14

6.  'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.

Authors:  A Sernicola; G Carnicelli; M Di Fraia; C Chello; C Furlan; R Muharremi; G Paolino; T Grieco
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-08       Impact factor: 9.228
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.